Cargando…

Dracorhodin perchlorate inhibits osteoclastogenesis through repressing RANKL‐stimulated NFATc1 activity

Osteolytic skeletal disorders are caused by an imbalance in the osteoclast and osteoblast function. Suppressing the differentiation and resorptive function of osteoclast is a key strategy for treating osteolytic diseases. Dracorhodin perchlorate (D.P), an active component from dragon blood resin, ha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Yuhao, Wang, Ziyi, Ma, Chao, Wei, Zhenquan, Chen, Kai, Wang, Chao, Zhou, Chi, Chen, Leilei, Zhang, Qingwen, Chen, Zhenqiu, He, Wei, Xu, Jiake
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7131942/ https://www.ncbi.nlm.nih.gov/pubmed/31965715 http://dx.doi.org/10.1111/jcmm.15003

Ejemplares similares

Maackiain dampens osteoclastogenesis via attenuating RANKL‐stimulated NF‐κB signalling pathway and NFATc1 activity
por: Liu, Yuhao, et al.
Publicado: (2020)

Loureirin B suppresses RANKL-induced osteoclastogenesis and ovariectomized osteoporosis via attenuating NFATc1 and ROS activities
por: Liu, Yuhao, et al.
Publicado: (2019)

Asiatic Acid Inhibits OVX-Induced Osteoporosis and Osteoclastogenesis Via Regulating RANKL-Mediated NF-κb and Nfatc1 Signaling Pathways
por: Hong, Guoju, et al.
Publicado: (2020)

Dracorhodin perchlorate induces the apoptosis of glioma cells
por: Chen, Xin, et al.
Publicado: (2021)

Cycloastragenol Attenuates Osteoclastogenesis and Bone Loss by Targeting RANKL-Induced Nrf2/Keap1/ARE, NF-κB, Calcium, and NFATc1 Pathways
por: Wang, Gang, et al.
Publicado: (2022)

Cytochalasin Z11 inhibits RANKL-induced osteoclastogenesis via suppressing NFATc1 activation
por: Wang, Lu, et al.
Publicado: (2019)

Dracorhodin Perchlorate Accelerates Cutaneous Wound Healing in Wistar Rats
por: Jiang, Xiao-wen, et al.
Publicado: (2017)

Adseverin mediates RANKL-induced osteoclastogenesis by regulating NFATc1
por: Song, Min-Kyoung, et al.
Publicado: (2015)

Pharmacodynamics of Dracorhodin Perchlorate and Its Inflammation-Targeting Emulsion Gel for Wound Healing
por: Wang, Xiaojie, et al.
Publicado: (2022)

Madecassoside inhibits estrogen deficiency‐induced osteoporosis by suppressing RANKL‐induced osteoclastogenesis
por: Wang, Qingqing, et al.
Publicado: (2018)

Evodiamine inhibits RANKL‐induced osteoclastogenesis and prevents ovariectomy‐induced bone loss in mice
por: Jin, Haiming, et al.
Publicado: (2018)

Betulinic Acid Protects From Bone Loss in Ovariectomized Mice and Suppresses RANKL-Associated Osteoclastogenesis by Inhibiting the MAPK and NFATc1 Pathways
por: Wei, Jiyong, et al.
Publicado: (2020)

Combined metabolomics and network pharmacology to elucidate the mechanisms of Dracorhodin Perchlorate in treating diabetic foot ulcer rats
por: Deng, Pin, et al.
Publicado: (2022)

Astilbin prevents bone loss in ovariectomized mice through the inhibition of RANKL‐induced osteoclastogenesis
por: Jin, Haiming, et al.
Publicado: (2019)

Dracorhodin Perchlorate Induced Human Breast Cancer MCF-7 Apoptosis through Mitochondrial Pathways
por: Yu, Jing-hua, et al.
Publicado: (2013)

Inhibitory Effects of Rhaponticin on Osteoclast Formation and Resorption by Targeting RANKL-Induced NFATc1 and ROS Activity
por: He, Jianbo, et al.
Publicado: (2021)

Peiminine Suppresses RANKL-Induced Osteoclastogenesis by Inhibiting the NFATc1, ERK, and NF-κB Signaling Pathways
por: Zhu, Mengbo, et al.
Publicado: (2021)

TGFβ1 Regulates Human RANKL-Induced Osteoclastogenesis via Suppression of NFATc1 Expression
por: Tokunaga, Tadahiro, et al.
Publicado: (2020)

Asperpyrone A attenuates RANKL‐induced osteoclast formation through inhibiting NFATc1, Ca(2+) signalling and oxidative stress
por: Chen, Xi, et al.
Publicado: (2019)

In vivo pro-angiogenic effects of dracorhodin perchlorate in zebrafish embryos: A novel bioactivity evaluation platform for commercial dragon blood samples
por: Krishnaraj, Preethi, et al.
Publicado: (2018)

Anemonin Attenuates RANKL-Induced Osteoclastogenesis and Ameliorates LPS-Induced Inflammatory Bone Loss in Mice via Modulation of NFATc1
por: Hou, Huanhuan, et al.
Publicado: (2020)

Vindoline Inhibits RANKL-Induced Osteoclastogenesis and Prevents Ovariectomy-Induced Bone Loss in Mice
por: Zhan, Yunfei, et al.
Publicado: (2020)

Angelica sinensis extract inhibits RANKL-mediated osteoclastogenesis by down-regulated the expression of NFATc1 in mouse bone marrow cells
por: Kong, Lingbo, et al.
Publicado: (2014)

STIM1 controls calcineurin/Akt/mTOR/NFATC2-mediated osteoclastogenesis induced by RANKL/M-CSF
por: Huang, Yanjiao, et al.
Publicado: (2020)

Dracorhodin perchlorate enhances wound healing via β-catenin, ERK/p38, and AKT signaling in human HaCaT keratinocytes
por: Lu, Chi-Cheng, et al.
Publicado: (2021)

A novel RANKL‐targeted flavonoid glycoside prevents osteoporosis through inhibiting NFATc1 and reactive oxygen species
por: Hong, Guoju, et al.
Publicado: (2021)

Dracorhodin Perchlorate Regulates the Expression of Inflammatory Cytokines through the TLR4 Pathway and Improves Skin Wound Healing in Diabetic Rats
por: Xiong, Zongliang, et al.
Publicado: (2022)

Sec-O-Glucosylhamaudol Inhibits RANKL-Induced Osteoclastogenesis by Repressing 5-LO and AKT/GSK3β Signaling
por: Cao, Jinjin, et al.
Publicado: (2022)

Agelasine D Suppresses RANKL-Induced Osteoclastogenesis via Down-Regulation of c-Fos, NFATc1 and NF-κB
por: Kang, Moo Rim, et al.
Publicado: (2014)

12-Deoxyphorbol-13-Hexadecanoate Abrogates OVX-Induced Bone Loss in Mice and Osteoclastogenesis via Inhibiting ROS Level and Regulating RANKL-Mediated NFATc1 Activation
por: He, Qi, et al.
Publicado: (2022)

Inhibition of RANKL-Induced Osteoclastogenesis by Novel Mutant RANKL
por: Jang, Yuria, et al.
Publicado: (2021)

Follicle-Stimulating Hormone Does Not Impact RANKL-Induced Osteoclastogenesis
por: Zhou, Ziyue, et al.
Publicado: (2021)

NF-κB inhibitor dehydroxymethylepoxyquinomicin suppresses osteoclastogenesis and expression of NFATc1 in mouse arthritis without affecting expression of RANKL, osteoprotegerin or macrophage colony-stimulating factor
por: Kubota, Tetsuo, et al.
Publicado: (2007)

Umbelliferone Prevents Lipopolysaccharide-Induced Bone Loss and Suppresses RANKL-Induced Osteoclastogenesis by Attenuating Akt-c-Fos-NFATc1 Signaling
por: Kwak, Sung Chul, et al.
Publicado: (2019)

Sesamolin Protects Mice From Ovariectomized Bone Loss by Inhibiting Osteoclastogenesis and RANKL-Mediated NF-κB and MAPK Signaling Pathways
por: Yang, Xue, et al.
Publicado: (2021)

Parkin Inhibits RANKL-Induced Osteoclastogenesis and Ovariectomy-Induced Bone Loss
por: Hou, Weiduo, et al.
Publicado: (2022)

Chalcone T4 Inhibits RANKL-Induced Osteoclastogenesis and Stimulates Osteogenesis In Vitro
por: de Matos, Iolanda Augusta Fernandes, et al.
Publicado: (2023)

Mitf Induction by RANKL Is Critical for Osteoclastogenesis
por: Lu, Ssu-Yi, et al.
Publicado: (2010)

Icaritin ameliorates RANKL-mediated osteoclastogenesis and ovariectomy-induced osteoporosis
por: Huang, Jun-ming, et al.
Publicado: (2023)

Fucoidan Prevents RANKL-Stimulated Osteoclastogenesis and LPS-Induced Inflammatory Bone Loss via Regulation of Akt/GSK3β/PTEN/NFATc1 Signaling Pathway and Calcineurin Activity
por: Lu, Sheng-Hua, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_l8l7lest9e7pr7g72kkb9a5nbm